Concepedia

K. Luijtens

KL

12

Publications

1.1K

Citations

11

H-Index

1992

Active since

Affiliations

UCB Pharma (Belgium)(Current)

Leiden University Medical Center

Karolinska Institutet

UCB Pharma (United States)

Center for Rheumatology

K. Luijtens is an author at UCB Pharma (Belgium) specializing in statistics, business, and knowledge discovery.

Top concepts

Publications per year

1992–2015

12

Publications

12

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

Josef S Smolen, R. B. M. Landewé, Philip J. Mease et al. · Annals of the Rheumatic Diseases · 2008 · 489 citations · Full text

Correlation between Oxidized Low Density Lipoproteins and von Willebrand Factor in Chronic Renal Failure

Paul Holvoet, J Donck, Michèle Landeloos et al. · Thrombosis and Haemostasis · 1996 · 177 citations

The growth of the extramatrical mycelium of ectomycorrhizal fungi and the growth response of <i>Pinus sylvestris</i> L.

Jan V. Colpaert, Jozef A. Van Assche, K. Luijtens · New Phytologist · 1992 · 135 citations · Full text

, , +15

RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol

Theodore Pincus, Victoria Furer, Edward Keystone et al. · Arthritis Care & Research · 2011 · 78 citations

Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial

Désirée van der Heijde, Edward Keystone, Jeffrey R. Curtis et al. · The Journal of Rheumatology · 2012 · 72 citations · Full text

Rows per page

1–5 of 12